ClinicalTrials.gg
RecruitingNCT06994169Updated Jun 3, 2026

Glofitamab in Real Life

An observational study in Large B-cell Lymphoma, sponsored by The Lymphoma Academic Research Organisation. Recruiting at 30 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by The Lymphoma Academic Research Organisation · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Lymphoma, B-Cell by The Lymphoma Academic Research Organisation — 2 open to participants now, 4 under way, none of them phase 3. Lymphoma, B-Cell · The Lymphoma Academic Research Organisation.

Started
2025
the only one that year
Observational
2 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Lymphoma, B-Cell by The Lymphoma Academic Research Organisation, this one is the only one that started in 2025, is one of 2 observational ones, and was the 10th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

2 of the 10 studies in Lymphoma, B-Cell by The Lymphoma Academic Research Organisation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Lymphoma, B-Cell by The Lymphoma Academic Research Organisation, or all of them as a file.
02

Study summary

To date, more than 300 patients have been treated with Glofitamab in the Expanded Access Programme (EAP) in France. In this study, it is proposed to perform a retrospective analysis of some of these patients. The aim is to describe the efficacy and safety of Glofitamab in the largest reported real-world cohort, with an expected median follow-up of more than 9 months. Particular focus will be given to the relapsed or refractory chimeric antigen receptors-T (CAR-T) population to confirm the response rates (CRR: 35-39%) of Glofitamab in this population and to assess the optimal timing of therapy initiation [8, 15].

03

Conditions studied

  • Large B-cell Lymphoma

Browse trials for

Keywords

  • CAR-T
  • Glofitamab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

French patients enrolled in the EAP before 1st of November 2024 and treated with at least Obinutuzumab pretreatment and one infusion of Glofitamab for R/R DLBCL We expect to collect data from 200-250 patients from this population with a minimum of 6 months of follow-up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patient enrolled in the French Glofitamab EAP for R/R DLBCL before 2024 November 1st, 2024
  • patient who received at least Obinutuzumab pretreatment and one infusion of Glofitamab
  • adult patient
  • patient who is informed of the study and who did not oppose to their data collection

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
250 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Patients treated in EPA

    Patients treated in Expanded Access Program to Glofitamab

    Drug: Glofitamab

Interventions

  • Glofitamab received for DLBCL in Early Phase Access

06

What researchers measure

Primary outcomes

  1. Best Complete Response Rate (best CRR) during treatment, assessed by investigator according to Lugano 2014 criteria.

    Time frame: 6 months

Secondary outcomes

  1. Complete metabolic response rate and overall response rate (ORR) by investigator assessment according to Lugano 2014 criteria

    Time frame: 1 month, 2 months, 3 months, 6 months

  2. Progression-free survival (PFS)

    Time frame: 6 months

  3. Event-Free Survival (EFS)

    Time frame: 6 months

  4. Overall survival (OS)

    Time frame: 6 months

  5. immune effector cell-associated neurotoxicity syndrome (ICANS) rate

    Time frame: 6 months

  6. ≥ grade 2 Cytokine release syndrome (CRS) rate

    Time frame: 6 months

  7. intensive care unit (ICU) admission rate

    Time frame: 6 months

  8. rate and cause of rehospitalization due to an adverse event potentially related to Glofitamab,

    Time frame: 6 months

  9. number of significant medical events leading to hospitalization

    Time frame: 6 months

07

Study locations

30 of 30 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Mar 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
May 29, 2025
StartActual
Dec 1, 2025
Primary completionActual
Mar 27, 2026
CompletionEst.
Dec 30, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06994169
Lead sponsor
The Lymphoma Academic Research Organisation
Responsible party
Sponsor
First posted
May 29, 2025
Start date
Dec 1, 2025
Primary completion
Mar 27, 2026
Completion
Dec 30, 2026 (estimated)
Last update
Jun 3, 2026

Study contacts

PROJECT MANAGER
Contact
glorel@lysarc.org
+33 4 72 66 93 33
Guillaume MANSON, MD
study chair · Lymphoma Study Association
Gilles CROCHET, MD
study chair · The Lymphoma Academic Research Organisation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion